Neurology Central

European Commission approves first immunotherapy for high-risk neuroblastoma patients

0
The European Commission has approved dinutuximab beta for high risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy in Europe for this group of patients.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Leave A Comment